Fulcrum Therapeutics (FULC) Set to Announce Quarterly Earnings on Thursday

Fulcrum Therapeutics (NASDAQ:FULC) will likely be issuing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Fulcrum Therapeutics to announce earnings of ($0.0745) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.10). On average, analysts expect Fulcrum Therapeutics to post ($0.60) EPS for the current fiscal year and ($0.12) EPS for the next fiscal year.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ FULC opened at $3.64 on Tuesday. The stock’s 50-day simple moving average is $3.77 and its two-hundred day simple moving average is $6.05. Fulcrum Therapeutics has a twelve month low of $2.83 and a twelve month high of $15.74.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Thursday, October 15th. One analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $8.20.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for genetically driven diseases. The company’s research approach is based on selectively modulating gene expression to address the underlying biology of disease rather than targeting individual symptoms.

Fulcrum’s lead investigational program is losmapimod, an oral small-molecule therapy being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare and progressive genetic muscle disorder.